GLP-1 Receptor Agonist [EPC]

237938 reported adverse events

Drugs of this class: DULAGLUTIDE LIRAGLUTIDE SEMAGLUTIDE EXENATIDE TIRZEPATIDE (INSULIN DEGLUDEC AND LIRAGLUTIDE) INSULIN GLARGINE AND LIXISENATIDE ORAL SEMAGLUTIDE

These side effects are most commonly reported by patients taking drugs of the GLP-1 Receptor Agonist [EPC] class:

# Side effect Count
0 NAUSEA 35171
1 BLOOD GLUCOSE INCREASED 31415
2 WEIGHT DECREASED 20384
3 INJECTION SITE PAIN 17295
4 VOMITING 15664
5 DIARRHOEA 14423
6 INCORRECT DOSE ADMINISTERED 14228
7 DECREASED APPETITE 13198
8 OFF LABEL USE 10191
9 INJECTION SITE HAEMORRHAGE 9736
See all common reactions for GLP-1 Receptor Agonist [EPC]

Drugs of the GLP-1 Receptor Agonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 EARLY SATIETY 703 0.4435
1 GLYCOSYLATED HAEMOGLOBIN ABNORMAL 282 0.3490
2 ACCIDENTAL UNDERDOSE 2427 0.3315
3 DRUG DELIVERY SYSTEM ISSUE 310 0.2645
4 ERUCTATION 3621 0.2587
5 GLYCOSYLATED HAEMOGLOBIN DECREASED 314 0.2520
6 GLYCOSYLATED HAEMOGLOBIN INCREASED 5043 0.2456
7 INJECTION SITE INJURY 845 0.2421
8 WEIGHT LOSS POOR 666 0.2406
9 PANCREATIC CARCINOMA METASTATIC 607 0.2378
See all enriched reactions for GLP-1 Receptor Agonist [EPC]